Breast Health

COVID-19

Cervical Health 

Contraception

Curbside Consults

Dermatology

Drug Pipeline News

Endometriosis

Genetic Testing

Gynecologic Oncology

Gynecology

Fetal Imaging

Abnormal Obstetrical Ultrasound

Ultrasound

Women's Imaging

Breast Imaging

Women's Ultrasound

Imaging

Infertility

LARC

Legally Speaking

Life Transitions

Malpractice

Menopause

Mental Health

Noninvasive Prenatal Testing

Obstetrics

Opinion

Osteoporosis

Pediatrics

Practice Management

Pregnancy and Birth

Sexual Health

Sexually Transmitted Infections

Surgery

Technology

Urology

Uterine Fibroids

Vulvovaginal Disease

Well Woman

About

News

Media

Podcasts

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Videos

Conferences

Conference Coverage

Conference Listing

Publications

Contemporary OB/GYN® Journal

Digital Supplements

CME/CE

Resources

Physician Fact Sheets

Interactive Tools

Supplements and Featured Publications

Subscribe

Editorial Board

Partnerships

Discover how innovative self-collection methods and the BD Onclarity HPV assay are breaking barriers in cervical cancer screening, empowering underserved communities with accessible and accurate care.

Transforming cervical cancer protection with the BD Onclarity HPV Assay

Articles

A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.

Maternal sFLT1 and EDN1 linked to late-onset preeclampsia

A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.

Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Contemporary OB/GYN week in review: IUD placement, UTI misinformation, and more

Advertise

Contact Us

Job Board

Terms of Use

Privacy Policy

Do Not Sell My Personal Information

Contemporary OB/GYN

Facebook

LinkedIn

RSS Feed

Spotlight

A Psychedelic to Treat Postpartum Depression?

CMV: In the Know

RSV Roundtable

STIs

Supplement: Closing the Gap in Cervical Cancer Screening

Vaginismus: Managing a Misunderstood and Underdiagnosed Condition

Why vNOTES Make Sense for My Patients

1rem

View

Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression 

Lan Coffman, MD, PhD, discusses results and clinical implications derived from the findings of the phase III MIRASOL trial.

Dr Coffman breaks down the findings from the phase III MIRASOL trial, and provides insight surrounding the treatment options and potential clinical implications surrounding ovarian cancer treatment.

Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression

Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression

EP: 1.Updated Phase III MIRASOL Trial Results: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression